Angela Cacace, Ph.D. is the Chief Scientific Officer at Arvinas. Angela has three decades of biopharmaceutical research experience, contributing to four marketed drugs and over 18 development candidates. At Arvinas, she led the Neuroscience team to deliver the first CNS penetrant PROTAC with the potential for treating neurodegeneration, ARV-102, into clinical development, and Platform biology research efforts driving innovative expansion of the targeted degrader small molecule platform. Before joining Arvinas, Angela served as the Vice President of Biology at Fulcrum Therapeutics, where, together with her team, she built the rare disease biology platform and delivered development candidates for Facioscapulohumeral Muscular Dystrophy and Sickle Cell Disease. Previously, she was the Director of Neuroscience and Genetically Defined Diseases at Bristol-Myers Squibb, where she spearheaded the tau platform and alternative therapeutic modalities and was a coinventor on several development candidate patents for novel antisense oligonucleotide molecules. Over her 20 years at Bristol-Myers Squibb, Angela held leadership positions of increasing responsibility, building research-wide teams, including centralized High Throughput Screening and lead optimization / early ADMET. While serving as a Sr. Principal Scientist in Cancer Biology at Pfizer, she was responsible for discovering a novel anti-angiogenic antibody development candidate. Angela received her Ph.D. in pharmacology from Columbia University and completed her postdoctoral research at Bristol-Myers Squibb and the National Cancer Institute.